The GLP-1 drug revolution is moving beyond weekly injections for wealthy markets. Upcoming pill-form versions will eliminate the need for refrigerated supply chains, opening up distribution in developing countries. Combined with expiring patents, this focus on form factor and cost will enable mass global adoption.

The surge in use of compounded GLP-1s, costing about half the price of branded versions, demonstrates huge untapped demand. Patients are willing to accept manufacturing and safety risks for affordability, proving price is a major barrier to adoption.

Wave Life Sciences' drug candidate reduced harmful visceral fat but failed to achieve significant overall body weight loss, a key FDA approval criterion. This outcome suggests that novel mechanisms targeting specific fat types, while scientifically interesting, are commercially unviable if they don't also deliver on the primary endpoint that regulators and patients expect.

A surprising driver of the burgeoning global obesity drug market, projected to hit $20 billion outside the U.S., is that it's almost entirely cash-pay. Consumers in countries like the UK are willing to spend hundreds of dollars per month out-of-pocket, demonstrating strong demand independent of traditional reimbursement systems.

Despite intense media hype and rapid initial sales, GLP-1 therapies have only reached a fraction of their potential market. With just 6% of eligible obesity patients in the U.S. and 2% internationally currently on treatment, the runway for future growth remains immense.

Widespread, subsidized distribution of GLP-1s to combat obesity could drastically cut national healthcare expenditures. Since a large portion of medical costs are linked to obesity, this health intervention could reduce the budget deficit more effectively than many economic policies.

The conversation frames GLP-1 weight-loss drugs not merely as a healthcare breakthrough but as a potential moonshot for the national economy. A mass government rollout could drastically reduce healthcare costs, improve mental health, and boost productivity, representing a powerful tool for social and economic policy with far-reaching ramifications.

Treating obesity with drugs like Wegovy for a limited time, such as two years, is akin to only treating high cholesterol temporarily. This policy ignores the medical reality that obesity is a chronic disease requiring lifelong management, not a short-term condition.

Medicare's temporary "Bridge" program funds weight loss drugs for seniors, but its eventual end will likely cause patients to regain weight. This negates the health benefits, potentially wasting the tens of billions of dollars spent on temporary coverage.